Entera Bio Ltd. Ordinary Shares (ENTX) Stock Price

ENTXStock

$2.68+11.20%52W

Market Cap$465.88M

P/E—

PEG Ratio—

Div yield—

Beta1.47

ENTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)127.26%

Price vs S&P 500 (4W)-8.13%

VGM Score31.91

Book Value / Share (Quarterly)$0.15

P/TBV (Annual)2.30x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-31.38%

Cash Flow / Share (Quarterly)$-0.22

Price vs S&P 500 (YTD)26.22%

Gross Margin (TTM)4.04%

Net Profit Margin (TTM)-4525.11%

EPS (TTM)$-0.35

10-Day Avg Trading Volume0.84M

EPS Excl Extra (TTM)$-0.35

Revenue Growth (5Y)-35.28%

EPS (Annual)$-0.25

ROI (Annual)-87.31%

Gross Margin (Annual)0.00%

Net Profit Margin (5Y Avg)-9546.37%

Cash / Share (Quarterly)$0.23

ROA (Last FY)-71.53%

Revenue Growth TTM (YoY)-76.80%

EBITD / Share (TTM)$-0.30

ROE (5Y Avg)-91.24%

Operating Margin (TTM)-4522.87%

Cash Flow / Share (Annual)$-0.16

P/B Ratio64.15x

P/B Ratio (Quarterly)12.01x

Net Income / Employee (Annual)$-571,900

EV / Revenue (TTM)2039.48x

Net Interest Coverage (TTM)-407.33x

ROA (TTM)-103.22%

EPS Incl Extra (Annual)$-0.25

Current Ratio (Annual)6.94x

Quick Ratio (Quarterly)8.88x

3-Month Avg Trading Volume2.01M

52-Week Price Return11.20%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.88

P/S Ratio (Annual)11097.91x

Asset Turnover (Annual)0.00x

52-Week High$4.20

Operating Margin (5Y Avg)-9584.75%

EPS Excl Extra (Annual)$-0.25

CapEx CAGR (5Y)16.43%

26-Week Price Return137.17%

Quick Ratio (Annual)6.93x

13-Week Price Return35.35%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)8.98x

Enterprise Value$454.80M

Revenue / Share Growth (5Y)-46.27%

Asset Turnover (TTM)0.02x

Book Value / Share Growth (5Y)-4.47%

Revenue / Employee (Annual)$2,100

Pretax Margin (Annual)-27235.71%

Cash / Share (Annual)$0.15

3-Month Return Std Dev192.77%

Gross Margin (5Y Avg)16.41%

Net Income / Employee (TTM)$-851,700

ROE (Last FY)-87.31%

Net Interest Coverage (Annual)-1.66x

EPS Basic Excl Extra (Annual)$-0.25

Receivables Turnover (TTM)0.67x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.35

Receivables Turnover (Annual)0.67x

ROI (TTM)-147.19%

P/S Ratio (TTM)2090.19x

Pretax Margin (5Y Avg)-9524.31%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.63

Price vs S&P 500 (52W)-4.33%

Year-to-Date Return38.14%

5-Day Price Return1.13%

EPS Normalized (Annual)$-0.25

ROA (5Y Avg)-79.03%

Net Profit Margin (Annual)-27235.71%

Month-to-Date Return-7.90%

Cash Flow / Share (TTM)$-0.34

EBITD / Share (Annual)$-0.25

Operating Margin (Annual)-27450.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-91.24%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.35

P/TBV (Quarterly)5.34x

P/B Ratio (Annual)6.79x

Pretax Margin (TTM)-4518.83%

Book Value / Share (Annual)$0.28

Price vs S&P 500 (13W)32.67%

Beta1.47x

Revenue / Share (TTM)$0.00

ROE (TTM)-147.19%

52-Week Low$0.91

vGradeF

gGradeF

mGradeA

vgmGradeD

ENTX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 7, 2026	-$0.08	-$0.14	-75.00%(-$0.06)
Q1 2026	May 8, 2026	-$0.08	-$0.07	+12.50%(+$0.01)
Q4 2025	Mar 27, 2026	-$0.09	-$0.06	+33.33%(+$0.03)
Q3 2025	Nov 14, 2025	-$0.09	-$0.07	+22.22%(+$0.02)
Q2 2025	Aug 8, 2025	-$0.11	-$0.06	+45.45%(+$0.05)

ENTX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.14

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ENTXEntera Bio Ltd. Ordinary Shares	F	F	A	2090.2x	-76.8%	4.0%	—	$2.68
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About Entera Bio Ltd. Ordinary Shares

Entera Bio is a clinical-stage biopharmaceutical company developing orally administered peptide therapeutics for chronic conditions, including osteoporosis and hypoparathyroidism. Its lead candidates are first-in-class mini tablet formulations of synthetic PTH (1-34) with tailored pharmacokinetic profiles, designed to offer patients a more convenient alternative to current injectable therapies.